Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Brompheniramine + pseudoephedrine + dextromethorphan** is a fixed-dose combination medication containing three active ingredients: an antihistamine (brompheniramine), a decongestant (pseudoephedrine), and a cough suppressant (dextromethorphan). It is used for the symptomatic relief of upper respiratory symptoms associated with allergies or the common cold, including cough, nasal congestion, runny nose, sneezing, and watery eyes[1][2][3]. **Mechanism of action:** *Brompheniramine* is an H1-receptor antagonist that blocks histamine at H1 receptors on effector cells in the respiratory tract, blood vessels, and GI tract. It also has anticholinergic effects that help dry secretions[4]. *Pseudoephedrine* acts as a sympathomimetic agent primarily on alpha-sympathetic receptors to cause vasoconstriction in nasal mucosa, reducing swelling and congestion[4]. *Dextromethorphan* acts centrally on the medullary cough center to suppress the cough reflex without analgesic or addictive properties[4]. The combination does not treat infections but provides short-term relief from allergy or cold symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brompheniramine + pseudoephedrine + dextromethorphan.